Is imepitoin effective for idiopathic epilepsy in cats?

In the first multicenter RCT (Charalambous 2026, n=37 cats), imepitoin produced a 62% responder rate (P=0.028), with mean seizure frequency falling from 6.1 to 3.0 per month. Phenobarbital achieved a higher 90% responder rate in the same study, making phenobarbital the more effective option in this head-to-head comparison.

How do the adverse event profiles of imepitoin and phenobarbital compare in cats?

In the Charalambous 2026 RCT, 88% of imepitoin-treated cats had adverse events (primarily ataxia and elevated ALT), compared to 90% of phenobarbital-treated cats. The difference between groups was not statistically significant, meaning overall AE burden was comparable despite mechanistic differences.

How does imepitoin's mechanism differ from phenobarbital in cats?

Imepitoin is a low-affinity partial GABA-A receptor agonist and high-affinity PDE10 inhibitor. Phenobarbital is a barbiturate-class GABA-A positive allosteric modulator with greater intrinsic efficacy. This mechanistic difference likely underlies imepitoin's lower but still clinically meaningful seizure reduction.

Imepitoin vs Phenobarbital for Feline Epilepsy: First Multicenter RCT Results (2026)

TL;DR

The first multicenter RCT comparing imepitoin to phenobarbital in cats with idiopathic epilepsy (Charalambous 2026, n=37) found a 62% imepitoin responder rate (P=0.028, mean seizure frequency 6.1 to 3.0 per month); phenobarbital achieved a 90% responder rate. Adverse event rates were 88% for imepitoin (ataxia, elevated ALT) and 90% for phenobarbital.

What just dropped

Charalambous and colleagues (2026) published the first multicenter RCT of imepitoin vs phenobarbital in cats with idiopathic epilepsy (n=37). The imepitoin responder rate was 62% (P=0.028); mean seizure frequency fell from 6.1 to 3.0 per month. Phenobarbital achieved a 90% responder rate (P=0.036 for seizure day reduction comparison). (https://pubmed.ncbi.nlm.nih.gov/41728120/)
Adverse events: imepitoin 88% AE rate (ataxia and elevated ALT); phenobarbital 90% AE rate. (https://pubmed.ncbi.nlm.nih.gov/41728120/)

Context

Imepitoin (Pexion) was first licensed for canine idiopathic epilepsy. Its use in cats has been explored off-label and more recently studied in a structured clinical setting. The drug acts as a low-affinity partial agonist at GABA-A receptors and as a high-affinity PDE10 inhibitor — a distinct mechanism from phenobarbital (barbiturate-class GABA-A positive allosteric modulator).

The Charalambous 2026 head-to-head RCT positions imepitoin as an active but second-tier option in cats relative to phenobarbital: the 62% responder rate demonstrates clinically meaningful seizure reduction, while phenobarbital's 90% rate reflects its higher intrinsic efficacy at the GABA-A receptor. The clinical decision between these two agents involves more than efficacy alone: phenobarbital carries established hepatic monitoring requirements, and individual patient risk-benefit assessment guides choice. Both drugs produced adverse events at high rates (88% and 90% respectively), with imepitoin's events being ataxia and hepatic enzyme elevation.

This RCT builds on the study population previously described in the June 2026 imepitoin feline epilepsy update and provides the full head-to-head phenobarbital comparison.

What this changes for clinicians managing feline idiopathic epilepsy

The Charalambous 2026 study provides the first multicenter RCT comparative evidence for imepitoin in cats — qualitatively different from earlier case-series literature. For clinicians using imepitoin off-label in cats with idiopathic epilepsy, this adds a reference point for expected responder rates and adverse events relative to the established phenobarbital standard.

See also: imepitoin-canine-idiopathic-epilepsy (https://www.thevoyage.ai/forvets/knowledge/imepitoin-canine-idiopathic-epilepsy)

References

Charalambous M et al. 2026. First multicenter RCT of imepitoin vs phenobarbital in feline idiopathic epilepsy. PMID 41728120. https://pubmed.ncbi.nlm.nih.gov/41728120/

Update (June 13, 2026): First Multicenter RCT Comparing Imepitoin to Phenobarbital in Cats With Idiopathic Epilepsy — Responder Rates and AE Profile

TL;DR

What just dropped

Context

What this changes for clinicians managing feline idiopathic epilepsy

References

Related reads

References

More clinical updates

Update (June 13, 2026): Bedinvetmab Produces Equivalent OA Pain Control With Fewer Adverse Events Than Meloxicam in Head-to-Head RCT

Update (June 13, 2026): Lokivetmab Maintains Pruritus Control in 87% of Dogs Across 12 Months — Cohort Data

Update (June 13, 2026): Robenacoxib Reduces Owner-Assessed Disability 49% and Improves Activity Counts in Cats With DJD

Update (June 13, 2026): Cyclosporine Pharmacokinetics in Cats — C4h Best Correlates With AUC, Safety Margin at Label Doses